Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Galectin-344 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00562 | 35046474 | Sci Rep | Hepatic galectin-3 is associated with lipid droplet area in non-alcoholic steatohepatitis in a new swine model. | 2022 | Details |
| A00775 | 34971904 | Biochem Biophys Res Commun | Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease. | 2021 | Details |
| A01665 | 34662732 | Environ Toxicol Pharmacol | Deciphering the toxicological role of Porphyromonas gingivalis derived endotoxins in liver diseases. | 2021 | Details |
| A02201 | 34462492 | Sci Rep | Deletion of RAGE fails to prevent hepatosteatosis in obese mice due to impairment of other AGEs receptors and detoxifying systems. | 2021 | Details |
| A02768 | 34250613 | J Clin Periodontol | Elimination of Porphyromonas gingivalis inhibits liver fibrosis and inflammation in NASH. | 2021 | Details |
| A03468 | 33991615 | Cell Signal | Secretory Galectin-3 promotes hepatic steatosis via regulation of the PPARγ/CD36 signaling pathway. | 2021 | Details |
| A04016 | 33788377 | Liver Int | Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis. | 2021 | Details |
| A04239 | 33693708 | J Clin Endocrinol Metab | Circulating Galectin-3 Levels Are Not Associated With Nonalcoholic Fatty Liver Disease: A Mendelian Randomization Study. | 2021 | Details |
| A04450 | 33612037 | Expert Rev Clin Pharmacol | Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis. | 2021 | Details |
| A05525 | 33218405 | Taiwan J Obstet Gynecol | Elevated serum levels of galectin-3 binding protein are associated with insulin resistance in non-diabetic women after menopause. | 2020 | Details |
| A05574 | 33203036 | Int J Mol Sci | ASC, IL-18 and Galectin-3 as Biomarkers of Non-Alcoholic Steatohepatitis: A Proof of Concept Study. | 2020 | Details |
| A08371 | 32139740 | Sci Rep | Odontogenic infection by Porphyromonas gingivalis exacerbates fibrosis in NASH via hepatic stellate cell activation. | 2020 | Details |
| A09074 | 31883514 | BMC Gastroenterol | Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH. | 2019 | Details |
| A09087 | 31881201 | Exp Mol Pathol | Alpha-syntrophin deficiency protects against non-alcoholic steatohepatitis associated increase of macrophages, CD8+ T-cells and galectin-3 in the liver. | 2019 | Details |
| A09265 | 31812510 | Gastroenterology | Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension. | 2019 | Details |
| A10434 | 31337151 | Int J Mol Sci | The Number of Liver Galectin-3 Positive Cells Is Dually Correlated with NAFLD Severity in Children. | 2019 | Details |
| A10589 | 31279739 | Metabolism | Laparoscopic sleeve gastrectomy reverses non-alcoholic fatty liver disease modulating oxidative stress and inflammation. | 2019 | Details |
| A12835 | 30261763 | Expert Rev Gastroenterol Hepatol | An update on the recent advances in antifibrotic therapy. | 2018 | Details |
| A12898 | 30235807 | Diseases | Emerging Therapeutic Targets and Experimental Drugs for the Treatment of NAFLD. | 2018 | Details |
| A13939 | 29679552 | Clin Biochem | Serum retinol binding protein 4 and galectin-3 binding protein as novel markers for postmenopausal nonalcoholic fatty liver disease. | 2018 | Details |
| A14512 | 29375205 | World J Gastroenterol | INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis. | 2018 | Details |
| A14513 | 29375204 | World J Gastroenterol | Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. | 2018 | Details |
| A17151 | 27956794 | World J Gastroenterol | Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis. | 2016 | Details |
| A17459 | 27778367 | Aliment Pharmacol Ther | Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis. | 2016 | Details |
| A17683 | 27660122 | Diabetes Care | Fatty Liver and Chronic Kidney Disease: Novel Mechanistic Insights and Therapeutic Opportunities. | 2016 | Details |
| A17760 | 27615366 | Hepatol Res | Establishment of mouse Mac-2 binding protein enzyme-linked immunosorbent assay and its application for mouse chronic liver disease models. | 2016 | Details |
| A17857 | 27521506 | Clin Gastroenterol Hepatol | New Pharmacologic Agents That Target Inflammation and Fibrosis in Nonalcoholic Steatohepatitis-Related Kidney Disease. | 2016 | Details |
| A19740 | 26380042 | World J Hepatol | Targeting Kupffer cells in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why and how? | 2015 | Details |
| A20127 | 26138749 | Expert Rev Gastroenterol Hepatol | In search of the magic bullet: can liver inflammation and fibrosis be reversed with medications? | 2015 | Details |
| A20355 | 26018806 | Mol Med | Galectin-3 Ablation Enhances Liver Steatosis, but Attenuates Inflammation and IL-33-Dependent Fibrosis in Obesogenic Mouse Model of Nonalcoholic Steatohepatitis. | 2015 | Details |
| A22317 | 24668763 | Hepatology | Endogenous annexin A1 is a novel protective determinant in nonalcoholic steatohepatitis in mice. | 2014 | Details |
| A22706 | 24367597 | PLoS One | Therapy of experimental NASH and fibrosis with galectin inhibitors. | 2013 | Details |
| A24692 | 22593713 | ScientificWorldJournal | Deficiency in galectin-3 promotes hepatic injury in CDAA diet-induced nonalcoholic fatty liver disease. | 2012 | Details |
| A25618 | 21635880 | Clin Biochem | Serum galectin-3 levels in patients with nonalcoholic fatty liver disease. | 2011 | Details |
| A26073 | 21145823 | J Hepatol | Galectin-3 ablation protects mice from diet-induced NASH: a major scavenging role for galectin-3 in liver. | 2010 | Details |
| A27329 | 18637146 | Hepatol Res | Nonalcoholic steatohepatitis and hepatocellular carcinoma in galectin-3 knockout mice. | 2008 | Details |
| A27917 | 17029217 | J Pathol | Disrupted galectin-3 causes non-alcoholic fatty liver disease in male mice. | 2006 | Details |
| A31100 | 31227742 | Sci Rep | Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH. | 2019 | Details |
| A42613 | 34019644 | J Clin Endocrinol Metab | Galectin-3 in NAFLD: Therapeutic Target or Noncausal Biomarker? | 2021 | Details |
| A48001 | 26844528 | Hepatology | Oncogenic driver genes and the inflammatory microenvironment dictate liver tumor phenotype. | 2016 | Details |
| A48924 | 24379606 | World J Gastroenterol | Hierarchical and selective roles of galectins in hepatocarcinogenesis, liver fibrosis and inflammation of hepatocellular carcinoma. | 2013 | Details |
| A50241 | 35461369 | Sci Rep | Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis. | 2022 | Details |
| A50302 | 35438166 | Clin Sci (Lond) | Annexin A1 treatment prevents the evolution to fibrosis of experimental nonalcoholic steatohepatitis. | 2022 | Details |
| A51458 | 34567824 | Liver Res | Overexpression of Galectin-1 and Galectin-3 in hepatocellular carcinoma. | 2020 | Details |